389 related articles for article (PubMed ID: 17225981)
1. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
[TBL] [Abstract][Full Text] [Related]
2. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
3. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
[TBL] [Abstract][Full Text] [Related]
4. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
5. Radical surgery does not recover immunodeficiency associated with gastric cancer.
Romano F; Caprotti R; Bravo AF; Conti M; Colombo G; Piacentini G; Uggeri F; Uggeri F
J Exp Clin Cancer Res; 2003 Jun; 22(2):179-83. PubMed ID: 12866567
[TBL] [Abstract][Full Text] [Related]
6. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
Ichihara F; Kono K; Takahashi A; Kawaida H; Sugai H; Fujii H
Clin Cancer Res; 2003 Oct; 9(12):4404-8. PubMed ID: 14555512
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma.
Hyakudomi M; Matsubara T; Hyakudomi R; Yamamoto T; Kinugasa S; Yamanoi A; Maruyama R; Tanaka T
Ann Surg Oncol; 2008 Jun; 15(6):1775-82. PubMed ID: 18363071
[TBL] [Abstract][Full Text] [Related]
8. Effect of bariatric surgery on peripheral blood lymphocyte subsets in women.
Merhi ZO; Durkin HG; Feldman J; Macura J; Rodriguez C; Minkoff H
Surg Obes Relat Dis; 2009; 5(2):165-71. PubMed ID: 18996763
[TBL] [Abstract][Full Text] [Related]
9. Characterization of immune responses in gastric cancer patients: a possible impact of H. pylori to polarize a tumor-specific type 1 response?
van den Engel NK; Winter H; Rüttinger D; Shau I; Schiller M; Mayer B; Moudgil T; Meimarakis G; Stolte M; Jauch KW; Fox BA; Hatz RA
Clin Immunol; 2006 Sep; 120(3):285-96. PubMed ID: 16765089
[TBL] [Abstract][Full Text] [Related]
10. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
Al-Shibli KI; Donnem T; Al-Saad S; Persson M; Bremnes RM; Busund LT
Clin Cancer Res; 2008 Aug; 14(16):5220-7. PubMed ID: 18698040
[TBL] [Abstract][Full Text] [Related]
12. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood.
Sun CF; Hsieh YY; Ngan KW; Wang WT
Ann Clin Lab Sci; 2001 Apr; 31(2):171-8. PubMed ID: 11337907
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
Anraku M; Cunningham KS; Yun Z; Tsao MS; Zhang L; Keshavjee S; Johnston MR; de Perrot M
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):823-9. PubMed ID: 18374762
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
15. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
Kapoor S; Pal S; Sahni P; Dattagupta S; Kanti Chattopadhyay T
J Surg Res; 2005 Dec; 129(2):172-5. PubMed ID: 15882879
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
18. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
[TBL] [Abstract][Full Text] [Related]
19. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
